Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.

Article  PubMed  Google Scholar 

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England) 2020;396(10258):1204-22.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik J. Nivolumab Plus Relatlimab: First Approval. Drugs. 2022;82(8):925–31.

Article  CAS  PubMed  Google Scholar 

Uhara H, Tsuchida T, Kiyohara Y, Akamatsu A, Sakamoto T, Yamazaki N. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: final analysis of a post-marketing surveillance. J Dermatol. 2022;49(9):862–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chamoto K, Yaguchi T, Tajima M, Honjo T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immunol. 2023;23(10):682–95.

Article  CAS  PubMed  Google Scholar 

US Food & Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. https://www.fda.gov/media/82647/download. Assessed 1 Mar 2024.

Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52: 151939.

Article  CAS  PubMed  Google Scholar 

US Food & Drug Administration. Opdivo (nivolumab) Injection Clinical Pharmacology Biopharmaceutics Review. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000ClinPharmR.pdf. Assessed 1 Mar 2024.

US Food & Drug Administration. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 5.0. 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Assessed 1 Mar 2024.

Gunturi A, McDermott DF. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2015;24(2):253–60.

Article  CAS  PubMed  Google Scholar 

Fong C, Cunningham D. Chemotherapy with nivolumab in advanced gastro-oesophageal adenocarcinoma. Lancet (London, England). 2021;398(10294):2–3.

Article  CAS  PubMed  Google Scholar 

Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;389(6):504–13.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Assessed 15 Mar 2024.

Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacomet Syst Pharmacol. 2017;6(1):58–66.

Article  CAS  Google Scholar 

US Food & Drug Administration. OPDIVO (nivolumab) injection, Highlights of prescribing information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s128lbl.pdf. Assessed 20 Jan 2024.

US Food & Drug Administration. Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products-Developing and Validating Assays for Anti-Drug Antibody Detection. 2019. https://www.fda.gov/media/119788/download. Assessed 25 July 2024.

U.S. Department of Health and Human Services. Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. 2014. https://www.fda.gov/media/85017/download. Accessed 8 Mar 2024.

Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2017;57(3):394–400.

Article  CAS  PubMed  Google Scholar 

Moschetti V, Buschke S, Bertulis J, Hohl K, McCabe D. Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF). Expert Opin Biol Ther. 2024;24(7):673–9.

Article  CAS  PubMed  Google Scholar 

Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77(6):914–21.

CAS  PubMed  Google Scholar 

Fleischmann RM, Saikali W, Lakhanpal S, Alvarez DF, Cox DS, Ianos CA, et al. Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study. Lancet Rheumatol. 2023;5(9):e532–41.

Article  CAS  PubMed  Google Scholar 

U.S. Department of Health and Human Services. Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling — Content and Format Guidance for Industry. 2022. https://www.fda.gov/media/155871/download. Assessed 8 Apr 2024.

Vande CN. Assays for measurement of TNF antagonists in practice. Frontline Gastroenterol. 2017;8(4):236–42.

Article  Google Scholar 

Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW. Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine. BioDrugs Clin Immunotherap Biopharm Gene Therapy. 2022;36(6):731–48.

Google Scholar